USA flag logo/image

An Official Website of the United States Government

Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R44AI090719
Solicitation Year:
2012
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-123
Small Business Information
CRESTONE, INC.
12635 E. Montview Blvd AURORA, CO -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic
Agency: HHS
Contract: 2R44AI090719-03
Award Amount: $3,000,000.00
 

Abstract:

DESCRIPTION (provided by applicant): The alarming increase in incidence of infections caused by drug-resistant bacteria has created an urgent need for new antibacterial agents. We are developing a novel class of small molecule antibiotics ( TZUs ) targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. These agents exhibit broad-spectrum activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), Streptococcus pyogenes (Group A strep), vancomycin resistant enterococcus (VRE), Bacillus anthracis, Listeria monocytogenes and Clostridium difficile. TZUs demonstrate bactericidal activity, oral bioavailability, in vivo efficacy, a low propensity fortoxicity and a low rate of spontaneous resistance. TZUs inhibit a novel bacterial target, thereby circumventing existing mechanisms of antibiotic resistance. We have made compelling progress during Phase I, having already met several key goals. In particular, we have identified several TZUs with in vitro potency exceeding that of linezolid, the only orally active drug approved for MRSA. We seek Phase II funding to enable completion of pivotal studies required for filing of an Investigational New Drug (IND)application. The research plan is divided into three stages. Aim 1 focuses on in-depth characterization of three top TZUs; each exhibits key attributes including in vivo efficacy following oral administration and outstanding microbiological potency. Aim 1studies will include in vivo pharmacodynamics (PD) dose response studies, determination of pharmacokinetic (PK) parameters in two species, determination of the PK-PD index, evaluation of in vitro and in vivo toxicity, and determination of rates of resistance development. Based on these results, the TZU that best exemplifies the target product profile will be selected as the IND candidate. In Aim 2, process chemistry work will commence, focusing on improving synthetic yields, lowering cost, and making the synthetic process more scalable (e.g., by elimination of chromatographic steps). At this stage, the goal will be to develop a synthetic route appropriate for 1-10 kilogram scale synthesis at a cost of less than 25,000 per kg. Exploratory toxicology and toxicokinetic studies will be performed under non-GLP conditions in two species to support dose selection, toxicology endpoints and toxicokinetic time points for GLP-compliant studies. Analytical and bioanalytical methods will be validated under Good Laboratory Practice (GLP) conditions. Comprehensive microbiological characterization will be performed, including MIC90 testing in several Gram-positive species, evaluation of cross-resistance, post antibiotic effect (PAE) and synergy with other antibiotics. In Aim 3, a 5-10 kg GLP-toxicology batch will be synthesized, and GLP-compliant toxicology and safety pharmacology studies will be performed. Successful completion of these IND-enabling studies would support advancement of this program into human clinical trials. This project represents a compelling opportunity to combat the rising tide of antibiotic-resistant infections, providing a much-needed public health benefit. PUBLIC HEALTH RELEVANCE: The alarming increase in incidence of infections caused by drug-resistant bacteria has created an urgent need for new antibacterial agents. The drug we wish to develop represents a brand new antibiotic class with broad-spectrum Gram-positive antibacterial activity. Existing bacterial populations are highly susceptible to this drug, highlighting the truly life-saving potential of this new agent.

Principal Investigator:

Thale C. Jarvis
720-289-8601
tjarvis@crestonepharma.com

Business Contact:

Jarvis Thale
720-289-8601
tjarvis@crestonepharma.com
Small Business Information at Submission:

CRESTONE, INC.
12635 E. Montview Blvd AURORA, CO -

EIN/Tax ID: 126420758
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No